Revalon 400 mg Tablet
Revalon (Moxifloxacin) is a 4th generation synthetic broad spectrum, fluoroquinolone class of antibacterial drug. It has activity against a wide range of gram-positive, gram-negative, anaerobic and atypical bacteria including Mycoplasma pneumoniae. It acts by inhibiting topoisomerase II (DNA gyrase) and topoisomerase IV which are necessary for bacterial DNA replication, transcription & repair.
Revalon (Moxifloxacin) is indicated for the treatment of acute bacterial sinusitis, acute exacerbation of chronic bronchitis, community acquired pneumonia, uncomplicated & complicated skin and skin structure infections, complicated intra-abdominal infections and pelvic inflammatory disease.
Dosage & Administration
Acute bacterial sinusitis 400 mg once daily for 7-10 days.
Acute bacterial exacerbation of chronic bronchitis 400 mg once daily for 5-10 days.
Community-acquired pneumonia 400 mg once daily for 7-14 days.
Uncomplicated skin and skin structure infections 400 mg once daily for 7 days.
Complicated skin and skin structure infections 400 mg once daily for 7-21 days.
Complicated intra-abdominal infections 400 mg once daily for 5-14 days.
Pelvic inflammatory disease 400 mg once daily for 14 days.
No dose adjustment is necessary in patients with renal or hepatic impairment.
It is contraindicated in the patients with a history of hypersensitivity to Moxifloxacin or other quinolones.
Moxifloxacin may cause increased risk of tendinitis and tendon rupture. It should be discontinued if pain or inflammation in a tendon occurs. It should not be used in patients with known prolongation of the QT interval, patients with uncorrected hypokalemia and patients with receiving Class IA or Class III antiarrhythmic agents.
Common side effects of Moxifloxacin include nausea, vomiting, diarrhea, headache and dizziness.
Moxifloxacin absorption is decreased when administered with antacid, sucralfate, multivitamins and multivalent cations (e.g. iron or zinc). Moxifloxacin may enhance the risk of convulsions with NSAIDs and bleeding with warfarin. So concomitant use of Moxifloxacin with them should be avoided.
Pregnancy & Lactation
US FDA pregnancy category C. Moxifloxacin is not recommended during pregnancy & lactation.
Keep in a dry place, away from light and heat. Keep out of the reach of children.